Lung function declines quietly. Home spirometry and daily oximetry give your team the trend that turns an exacerbation from an admission into a medication adjustment.
The clinical value of home spirometry rests almost entirely on one design decision: comparing a patient against their own established baseline rather than against population reference norms. An FEV1 that looks unremarkable on a reference chart can represent a serious decline for the individual patient in front of you.
Get that right and a sustained fall against personal best becomes a reliable early signal. Get it wrong and the alert queue fills with noise your team learns to ignore inside a month.
Pulmonology programmes usually run spirometry and oximetry together, because lung function and oxygenation answer different questions. Most also run COPD pathways alongside asthma and interstitial disease on the same platform.
Effort quality decides everything. On-device coaching is what makes a home spirometry reading usable without a technician present, and it is the practical barrier that sinks most home spirometry programmes.
Four signals, each answering a different question about the same patient.
| Signal | Device | Common alert threshold | What the team does |
|---|---|---|---|
| FEV1 / FVC | Home spirometer | >10–15% decline vs personal best | Review trend and effort quality, consider a treatment course. |
| Peak flow | Same device | Sustained fall against personal best | Earlier and cruder than FEV1. Useful as a daily check. |
| Oxygen saturation | Pulse oximeter | <92% or a drop from baseline | Same-day contact. Confirms whether the decline is functional or gas exchange. |
| Inhaler / reliever use | Adherence sensor | Doubling of usual actuations | Often the earliest signal of all, and it is objective. |
| Symptom score | SMS or app check-in (RTM) | Worsening breathlessness or sputum | Structured triage against the action plan. |
Alert thresholds are configured per patient by the ordering clinician and adjusted over time. The values above are common starting points, not clinical guidance, and nothing here establishes a standard of care. Reimbursement figures are approximate national non-facility Medicare averages and vary by locality, facility status, payer and calendar year: verify current rates at cms.gov or with your MAC before you bill.
Cellular, coached and shipped activated.
FEV1, FVC and peak flow with on-device effort coaching, trended against personal best.
RTM 98976Clinical-grade SpO2 and pulse in under 30 seconds over LTE-M.
RPM 99454Inhaler actuation records that surface a flare before symptoms do.
RTM 98975Separates infection from bronchospasm during a suspected flare.
RPM 99454RTM and RPM cover different data types. Treatment-management time can’t be counted under both.
Respiratory device supply and symptom/adherence data.
98976 · 98980 · 98981Oximetry and other physiologic data.
99453 · 99454 · 99457Respiratory disease plus a second chronic condition.
99490 · 99439When the respiratory condition alone drives the burden.
99424–99427The 30 days after a respiratory admission.
99495 · 99496The first two weeks set the patient’s personal best. Alerting against population norms before that is meaningless.
The spirometer talks the patient through the manoeuvre, which is what makes the effort usable.
Cellular transmission with no app, counted toward the transmission threshold.
Rules key off percentage fall against personal best.
RTM and RPM time logged separately, never double-counted.
No, and it isn’t meant to. Home spirometry supplements formal PFTs by giving you a trend between visits; diagnostic-grade testing still happens in the lab.
What home spirometry adds is frequency. A decline that would have been discovered at the next appointment shows up within days, which is the difference between a medication adjustment and an admission.
On-device coaching walks the patient through the manoeuvre and flags efforts that do not meet quality criteria, and results are trended against that patient’s own established baseline rather than population norms.
Effort quality is the practical barrier that sinks most home spirometry programmes, so it is worth confirming how a vendor handles it before choosing devices.
Both, for different data. RTM covers non-physiologic data: therapy adherence, symptom scores and respiratory device supply under 98976, with management time under 98980 and 98981. RPM covers physiologic measurements such as oxygen saturation under 99453, 99454, 99457 and 99458.
The constraint that matters: RTM treatment-management time (98980/98981) cannot be the same time billed under RPM (99457/99458). Track them separately.
Patients with a history of exacerbations, those recently discharged after a respiratory admission, and patients whose adherence is uncertain. Frequency of prior exacerbation is the strongest single predictor of the next one, which makes it the most useful enrolment filter.
Interstitial lung disease patients are a growing group, since a slow decline against personal best is exactly what home trending is good at surfacing.
Bring your exacerbation-frequency data and we’ll scope the device mix, alert rules and RTM/RPM split.
Practical guidance on remote monitoring, devices and billing. Updated with every new post.
Compare RPM and CCM platforms on the five things that decide real-world performance, then implement an RPM program step by step with 2026 CPT rates.
Read articleCellular or Bluetooth for RPM blood pressure? What CPT 99445 changed in 2026, why 78% of over-65s owning a smartphone breaks the usual argument, and how to match devices per patient.
Read articleA measure-by-measure map of what RPM, CCM and APCM can actually influence, the CBP specification detail most programs miss, and why PDC targeting should start at 79%.
Read articleInterested in a demo or just general questions? Fill out the form below and a representative will respond shortly!
